ALPCO Diabetes Research Travel Grant

ALPCO strives to provide scientists and healthcare professionals with robust tools for their research and clinical diagnostic endeavors. We offer a wide range of testing solutions, presenting vital insights to advance research and improve clinical outcomes.

To further promote progressive diabetes and obesity research, ALPCO is sponsoring a new travel grant award program.

Fall 2018 Recipient: Stephen M. Grote

ALPCO awarded its inaugural Diabetes Research Travel Grant to Stephen M. Grote from the Saint Louis University School of Medicine.

Mr. Grote’s work with the novel peptide neuronostatin shows great promise to the diabetes research community. His research suggests that neuronostatin has an effect on glucagon synthesis and release, while also proposing that the peptide may have therapeutic potential in the treatment and prevention of hypoglycemia and alpha cell dysfunction in diabetes.

Mr. Grote’s Research

Hypoglycemia unawareness is a condition that occurs in individuals with diabetes, especially if they have repeatedly experienced hypoglycemic events. This condition is extremely dangerous as the individuals are not aware of their hypoglycemia since they lack the usual responses of sweating, dizziness, and shaking.

Hypoglycemia could be brought on by administration of too much insulin, or poor counterregulation. The normal counterregulatory response to low blood glucose is to increase glucagon release and secondarily mobilize glucose from the liver. This response is hindered in patients with diabetes. The only option in preventing or reversing hypoglycemia unawareness is careful avoidance of hypoglycemia through close monitoring–an often unobtainable goal.

Stephen’s work addresses the critical need for alternative therapies and a better understanding of diabetic hypoglycemia.

As eloquently described by Stephen’s mentor, Dr. Gina Yosten, “Stephen’s work has the potential to change the way in which diabetes is treated. His data suggests that neuronostatin is a novel counterregulatory factor that drives glucagon release as blood glucose levels fall. The loss of neuronostatin secretion or signaling in diabetes could lead to failure of glucagon release, which disrupts the ability of patients with diabetes to mount a proper counterregulatory response to low glucose, leading to dangerously low blood glucose levels, coma, and sometimes death.”

Stephen further explains, “We recently identified a novel peptide, neuronostatin (NST), encoded in the somatostatin preprohormone and produced by pancreatic delta cells. Through GPR107, an orphan G-protein coupled receptor we matched to the peptide, NST enhances proglucagon mRNA expression and glucagon release from isolated islets and immortalized alpha cells. The peptide also reduces beta cell release of insulin in response to high glucose conditions in isolated islets via an indirect effect on the alpha cell. Based off our findings, we hypothesize that NST is a pancreatic component of the counterregulatory response through enhanced glucagon release.

“Therefore, we carried out in vivo studies to better determine the role of NST in the counterregulatory response. In rats, infused NST increases plasma glucose levels over a 30 minute time period. Additionally NST delays glucose clearance and diminishes the insulin response to hyperglycemia in a glucose tolerance test. Fasting blood glucose raises plasma NST levels in rats. Further experiments will continue to confirm the role of NST in preventing or reversing hypoglycemia and how it plays into the complex relationships of islet regulation and communication, particularly in human disease. With the effect of neuronostatin on glucagon synthesis and release, we propose that the peptide has therapeutic potential in the treatment and prevention of hypoglycemia and alpha cell dysfunction in diabetes.”

Apply for ALPCO’s Diabetes Research Travel Grant

A thumbnail preview of our diabetes travel grant program brochure.

Diabetes Research Travel Grant Brochure

Eligibility

All applicants must be currently enrolled graduate students, postdoctoral fellows, or early stage investigators* in North America and must be primarily responsible for the research described. All successful applicants must commit to submitting/presenting their results in the form of a scientific poster or oral presentation at a relevant diabetes conference within one year from award receipt. Conferences include: ADA, MIC, BIIC, ABC, and Keystone Symposia. Please inquire if you would like to propose an alternative conference. An applicant is eligible to receive one award per year.

Criteria

Competitive applications will describe active research which clearly and concisely demonstrates direct relevance to diabetes and obesity research, treatment and/or future therapies.

Award Features

The grant consists of:

  • $2,500 product credit for applicable ALPCO assays** (to be purchased within six months of award)
  • Up to $2,500 to present abstract/findings (to be used within one year of award), including:
    • Travel fees (airfare and lodging only)***
    • Conference registration fees***

Application Materials

Submissions must include the following:

Research Description

The description should include your abstract and a clear explanation of the connection between the research and its relevance to improving future diabetes and obesity treatment or therapies. The length of the proposal should not exceed two pages (including figures and references).

Advisor/Mentor Letter

We require that the applicant’s scientific advisor/mentor also send a letter confirming enrollment or postdoctoral status. The letter must detail the applicant’s contribution to the research, distinguishing it from the efforts of other supporting team members, and establishing the significance of the contribution to its relevant scientific discipline.

Deadlines

Complete applications should be submitted by the following deadlines.

  • March 31
  • June 30
  • September 30
  • December 31

The award winners will be announced 90 days after the application deadline.

Submission

Please email all application materials to: diabetesgrant@alpco.com.

A thumbnail preview of our diabetes travel grant application form.

Diabetes Research Travel Grant Application

Frequently Asked Questions

What does a complete application include?

Submissions must include the following:

  • Diabetes Research Travel Grant application
  • Research description: The description should include your abstract and a clear explanation of the connection between the research and its relevance to improving future diabetes and obesity treatment or therapies. The length of the proposal cannot exceed two pages (including figures and references).
  • Advisor/mentor letter: We require that the applicant’s scientific advisor/mentor also send a letter confirming enrollment or postdoctoral status. The letter must detail the applicant’s contribution to the research, distinguishing it from the efforts of other supporting team members, and establishing the significance of the contribution to its relevant scientific discipline.
  • Current resume/CV

How do I submit my application?

You can submit your application and submission materials to: diabetesgrant@alpco.com.

For additional information, please contact:

Christi Caillouette

Product Manager, Diabetes & Obesity

(800) 592-5726, x255

ccaillouette@alpco.com

What is the deadline for applications?

Complete applications should be submitted by the following deadlines.

  • March 31
  • June 30
  • September 30
  • December 31

When will I find out if I have been awarded a grant?

The award winners will be announced 90 days after the application deadline.

If I am awarded a grant, which shows can I choose to present at next year?

Conferences include: ADA, MIC, BIIC, ABC, and Keystone Symposia. Please inquire if you would like to propose an alternative conference.

If I receive a grant, how do I submit my receipts for reimbursement?

Please submit all receipts to diabetesgrant@alpco.com.

 

 

ALPCO reserves the right to change or discontinue the grant program at any time.

*Early stage investigators: less than 10 years from terminal degree.

**Applies to kits with a catalog number starting with “80-”.

***Award winners will be responsible for arranging their own travel, accommodations, and conference registration. Receipts will be required to receive reimbursement.